US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Medicines

84.90

0.0000

Volume:- -

Turnover:- -

Market Cap:6.79B

PE:-27.06

High:84.90

Open:84.90

Low:84.90

Close:84.90

52wk High:84.98

52wk Low:23.15

Shares:79.95M

Float Shares:74.86M

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):-3.1374

EPS(LYR):-1.6740

ROE:553.30%

ROA:-13.71%

PB:178.02

PE(LYR):-50.72

Loading ...

Overview Company News Filings

Everest Medicines (SEHK:1952) Valuation Check After Recent Share Price Volatility

Simply Wall St.

Nomura Adjusts BeOne Medicines Price Target to $442.91 From $366.06, Maintains Buy Rating

MT Newswires Live

Aodong Pharmaceutical's Subsidiary Gets Nod to Market 10 Traditional Chinese Medicines

MT Newswires Live

TYK Medicines Gets Regulatory Nod to List 4.6 Million Converted Shares on Hong Kong Bourse

MT Newswires Live

TYK Medicines Wins Approval for Full H-Share Circulation in Hong Kong

Press Release: BeOne Medicines to Announce Fourth Quarter and Full Year 2025 Financial Results on February 26

Everest Medicines Advances With Major Licensing Deal, New Drug Application Approval

Benzinga_recent_news

Is BeOne Medicines (ONC) Using InSysBio Partnership to Quietly Redefine Its R&D Risk Strategy?

Simply Wall St.

DBS Bank Starts BeOne Medicines at Buy with HK$290 Price Target

MT Newswires Live

TYK Medicines' Application for Lung Cancer Drug Accepted in China

MT Newswires Live

TYK Medicines’ Lung Cancer Drug Asandeutertinib NDA Accepted by China’s NMPA

Everest Medicines Announces China NMPA Approval of VELSIPITY® for Adults with Moderately to Severely Active Ulcerative Colitis

Everest Medicines Wins China Approval for Ulcerative Colitis Drug VELSIPITY and Outlines Ambitious 2030 Growth Plan

Everest Medicines Acquires License to Commercialize Kidney Drug MT1013

MT Newswires Live

Everest Medicines Announces Exclusive License Agreement with Micot to Commercialize MT1013

Everest Medicines Secures Exclusive Asian Rights to First-in-Class SHPT Drug MT1013

BeOne Medicines Is Maintained at Overweight by Barclays

Analysts Offer Insights on Healthcare Companies: Amgen (AMGN) and BeOne Medicines (ONC)

Everest Medicines Calls Virtual EGM to Approve Commercial Deal and New Share Incentive Plan

BeOne Medicines Extends InSysBio Tie Up To Refine Oncology Trial Dosing

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/MDCO/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MDCO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MDCO\",,,,,undefined,":{"symbol":"MDCO","market":"US","secType":"STK","nameCN":"Medicines","latestPrice":84.9,"timestamp":1578085200000,"preClose":84.9,"halted":3,"volume":0,"delay":0,"changeRate":0,"floatShares":74862655,"shares":79948329,"eps":-3.137449,"marketStatus":"Halted","change":0,"latestTime":"02-23 13:44:26 EST","open":84.9,"high":84.9,"low":84.9,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.137449,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1771880400000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":965707200000,"exchange":"NASDAQ","adjPreClose":84.9,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MDCO\",,,,,undefined,":{"symbol":"MDCO","floatShares":74862655,"roa":"-13.71%","roe":"553.30%","lyrEps":-1.673974,"shares":79948329,"dividePrice":0,"high":84.9,"amplitude":0,"preClose":84.9,"low":84.9,"week52Low":23.15,"pbRate":"178.02","week52High":84.98,"institutionHeld":1.2829,"latestPrice":84.9,"eps":-3.137449,"divideRate":0,"volume":0,"delay":0,"ttmEps":-3.137449,"open":84.9,"prevYearClose":84.94},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MDCO\",params:#limit:5,,,undefined,":[{"date":"2019-10-30","symbol":"MDCO","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":"2019/09","expectedEps":-0.84,"defaultRemindTime":1572422400000,"name":null,"time":"Pre-Market","dateTimestamp":1572408000000,"actualEps":null},{"date":"2019-07-24","symbol":"MDCO","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":"2019/06","expectedEps":-0.66,"defaultRemindTime":1563955200000,"name":null,"time":"Pre-Market","dateTimestamp":1563940800000,"actualEps":-0.67},{"market":"US","date":"2019-04-25","symbol":"MDCO","fiscalQuarterEnding":"2019/03","expectedEps":-0.71,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1556164800000,"reportTimeType":"pre","actualEps":-0.68},{"market":"US","date":"2019-02-27","symbol":"MDCO","fiscalQuarterEnding":"2018/12","expectedEps":-0.35,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1551243600000,"reportTimeType":"pre","actualEps":-0.67},{"market":"US","date":"2018-11-08","symbol":"MDCO","fiscalQuarterEnding":"2018/09","expectedEps":-0.48,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1541653200000,"reportTimeType":"pre","actualEps":-0.7}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MDCO\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MDCO\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MDCO\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2611130118","title":"Everest Medicines (SEHK:1952) Valuation Check After Recent Share Price Volatility","url":"https://stock-news.laohu8.com/highlight/detail?id=2611130118","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611130118?lang=en_us&edition=fundamental","pubTime":"2026-02-14 11:29","pubTimestamp":1771039772,"startTime":"0","endTime":"0","summary":"What is moving Everest Medicines after recent performance\nEverest Medicines (SEHK:1952) has caught investor attention after a recent 2.5% one-day return, which contrasts with a decline of about 17.8% over the past three months and a modest gain over the past year.\nSee our latest analysis for Everest Medicines.\nThat 2.5% one day share price gain comes after a 90 day share price return of about an 18% decline, while the 1 year total shareholder return of around 5% hints that shorter term...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1952/everest-medicines-shares/news/everest-medicines-sehk1952-valuation-check-after-recent-shar","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1952/everest-medicines-shares/news/everest-medicines-sehk1952-valuation-check-after-recent-shar","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1574","BK1583","MDCO","01952","BK1161"],"gpt_icon":0},{"id":"2611360151","title":"Nomura Adjusts BeOne Medicines Price Target to $442.91 From $366.06, Maintains Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2611360151","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611360151?lang=en_us&edition=fundamental","pubTime":"2026-02-13 20:05","pubTimestamp":1770984342,"startTime":"0","endTime":"0","summary":"Nomura Adjusts BeOne Medicines Price Target to $442.91 From $366.06, Maintains Buy Rating","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NMR","MDCO"],"gpt_icon":0},{"id":"2611218614","title":"Aodong Pharmaceutical's Subsidiary Gets Nod to Market 10 Traditional Chinese Medicines","url":"https://stock-news.laohu8.com/highlight/detail?id=2611218614","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611218614?lang=en_us&edition=fundamental","pubTime":"2026-02-13 11:54","pubTimestamp":1770954894,"startTime":"0","endTime":"0","summary":"Jilin Aodong Pharmaceutical's  subsidiary, Jilin Aodong Yanbian Pharmaceutical, obtained marketing registration certificates for 10 traditional Chinese medicines, according to a Shenzhen bourse filing on Friday.Some of the medicines getting the certificates are black nightshade granules, Tiankuizi Formula Granules, vinegar-artemisia charcoal formula granules, amomum tsao-ko  granules and honey rosehip formula granules.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0188","BK0086","BK0239","BK0028","000623","MDCO","BK0012","BK0201","BK0074"],"gpt_icon":0},{"id":"2610941557","title":"TYK Medicines Gets Regulatory Nod to List 4.6 Million Converted Shares on Hong Kong Bourse","url":"https://stock-news.laohu8.com/highlight/detail?id=2610941557","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610941557?lang=en_us&edition=fundamental","pubTime":"2026-02-12 18:00","pubTimestamp":1770890436,"startTime":"0","endTime":"0","summary":"TYK Medicines  obtained approval from the Listing Committee of the Hong Kong Stock Exchange to list over 4.6 million shares to be converted under the firm's Hong Kong-listed share full circulation.The shares, held by one shareholder, represent 1.21% of the pharmaceutical company's issued share capital, according to a Thursday Hong Kong bourse filing.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","MDCO","02410"],"gpt_icon":0},{"id":"2610949500","title":"TYK Medicines Wins Approval for Full H-Share Circulation in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2610949500","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610949500?lang=en_us&edition=fundamental","pubTime":"2026-02-12 17:39","pubTimestamp":1770889171,"startTime":"0","endTime":"0","summary":"TYK Medicines, Inc. Class H ( ($HK:2410) ) has provided an update. TYK Medicines, Inc., a PRC-incorporated joint stock company listed in Hong Kong,...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/tyk-medicines-wins-approval-for-full-h-share-circulation-in-hong-kong?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/tyk-medicines-wins-approval-for-full-h-share-circulation-in-hong-kong?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MDCO"],"gpt_icon":0},{"id":"2610193696","title":"Press Release: BeOne Medicines to Announce Fourth Quarter and Full Year 2025 Financial Results on February 26","url":"https://stock-news.laohu8.com/highlight/detail?id=2610193696","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610193696?lang=en_us&edition=fundamental","pubTime":"2026-02-11 19:01","pubTimestamp":1770807660,"startTime":"0","endTime":"0","summary":"BeOne Medicines Ltd. , a global oncology company, will report its fourth quarter and full year 2025 financial results on Thursday, February 26, 2026 before the financial markets open. Following the release of the financials, the Company will host a live webcast with management at 8:00 a.m. ET.This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding BeOne's plans, commitments, aspirations and goals related to BeOne's medicines and drug candidates. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors which are discussed in the section entitled \"Risk Factors\" in BeOne's most recent periodic report filed with the U.S. Securities and Exchange Commission  as well as discussions of potential risks, uncertainties, and other important factors in BeOne's subsequent filings with","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ONC","BK4526","BK4585","MDCO","BK4588"],"gpt_icon":0},{"id":"2610203656","title":"Everest Medicines Advances With Major Licensing Deal, New Drug Application Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2610203656","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610203656?lang=en_us&edition=fundamental","pubTime":"2026-02-09 22:02","pubTimestamp":1770645720,"startTime":"0","endTime":"0","summary":"The licensing deal will see Everest Medicines work exclusively withShaanxi Micot Pharmaceutical Technology Co. Ltd.to commercialize MT1013, which is the world's first-in-class dual-targeting receptor agonist polypeptide that simultaneously targets the Calcium-Sensing Receptor  and the Osteogenic Growth Peptide  receptor. The drug is primarily being developed to treat SHPT.According to the agreement, Everest Medicines will make an upfront payment of 200 million yuan to Micot, as well as potential regulatory and commercial milestone payments of up to 1.04 billion yuan. Micot will cover relevant development costs going forward for MT1013, which is currently in its Phase 3 clinical trials in China.Separately, Everest Medicines said last Friday that the NMPA had granted Velsipity an NDA to treat adults suffering from moderately to severely active UC who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.Everest's stock rose ","market":"us","thumbnail":"/next-assets/images/benzinga-post-card-placeholder.svg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["/next-assets/images/benzinga-post-card-placeholder.svg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/Opinion/26/02/50478566/everest-medicines-advances-with-major-licensing-deal-new-drug-application-approval","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/Opinion/26/02/50478566/everest-medicines-advances-with-major-licensing-deal-new-drug-application-approval","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["MDCO"],"gpt_icon":0},{"id":"2610653720","title":"Is BeOne Medicines (ONC) Using InSysBio Partnership to Quietly Redefine Its R&D Risk Strategy?","url":"https://stock-news.laohu8.com/highlight/detail?id=2610653720","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610653720?lang=en_us&edition=fundamental","pubTime":"2026-02-09 19:22","pubTimestamp":1770636159,"startTime":"0","endTime":"0","summary":"InSysBio recently announced it has extended its collaboration with BeOne Medicines to apply mechanistic translational modeling to support selection of minimal recommended starting doses, step-up dosing regimens, and dose-escalation clinical study design for cytokine release syndrome risk management.\nThis expanded partnership highlights how advanced modeling can shape early clinical decisions, potentially improving the efficiency and safety profile of BeOne Medicines’ development...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-onc/beone-medicines/news/is-beone-medicines-onc-using-insysbio-partnership-to-quietly","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-onc/beone-medicines/news/is-beone-medicines-onc-using-insysbio-partnership-to-quietly","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ONC","BK4585","BK4526","BK4139","MDCO"],"gpt_icon":0},{"id":"2610364986","title":"DBS Bank Starts BeOne Medicines at Buy with HK$290 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2610364986","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610364986?lang=en_us&edition=fundamental","pubTime":"2026-02-09 18:14","pubTimestamp":1770632047,"startTime":"0","endTime":"0","summary":"DBS Bank Starts BeOne Medicines at Buy with HK$290 Price Target","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RJAW.SI","MDCO","DBS"],"gpt_icon":0},{"id":"2609569027","title":"TYK Medicines' Application for Lung Cancer Drug Accepted in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2609569027","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609569027?lang=en_us&edition=fundamental","pubTime":"2026-02-06 18:00","pubTimestamp":1770372036,"startTime":"0","endTime":"0","summary":"TYK Medicines'  new drug application for Asandeutertinib was accepted by China's National Medical Products Administration, according to a Friday Hong Kong bourse filing.The acceptance is for the indication of first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02410","MDCO","BK1161"],"gpt_icon":0},{"id":"2609256667","title":"TYK Medicines’ Lung Cancer Drug Asandeutertinib NDA Accepted by China’s NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=2609256667","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609256667?lang=en_us&edition=fundamental","pubTime":"2026-02-06 17:08","pubTimestamp":1770368903,"startTime":"0","endTime":"0","summary":"TYK Medicines, Inc. Class H ( ($HK:2410) ) has shared an announcement. TYK Medicines has announced that China’s National Medical Products Administr...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/tyk-medicines-lung-cancer-drug-asandeutertinib-nda-accepted-by-chinas-nmpa?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/tyk-medicines-lung-cancer-drug-asandeutertinib-nda-accepted-by-chinas-nmpa?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MDCO"],"gpt_icon":0},{"id":"2609255528","title":"Everest Medicines Announces China NMPA Approval of VELSIPITY® for Adults with Moderately to Severely Active Ulcerative Colitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2609255528","media":"prnewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609255528?lang=en_us&edition=fundamental","pubTime":"2026-02-06 13:10","pubTimestamp":1770354600,"startTime":"0","endTime":"0","summary":"SHANGHAI, Feb. 6, 2026 /PRNewswire/ -- Everest Medicines , a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that China's National Medical Products Administration  has approved VELSIPITY  for the treatment of adult patients with moderately to severely active ulcerative colitis  who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.\"Ulcerative colitis is rapidly increasing in China and follows a relapsing course that significantly impairs quality of life and places a substantial burden on both patients and the healthcare system,\" said Prof. Chen Minhu, Academic Leader and Chief Expert of the Department of Gastroenterology at The First Affiliated Hospital of Sun Yat-sen University. \"Achieving mucosal healing is a widely recognized treatment goal in clinical guidelines, as it improves symptom control, reduces relapse ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/everest-medicines-announces-china-nmpa-approval-of-velsipity-for-adults-with-moderately-to-severely-active-ulcerative-colitis-302681009.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4226","BK4106","BK7057","LU0006061336.USD","MMS.AU","MDCO","MMS"],"gpt_icon":0},{"id":"2609855802","title":"Everest Medicines Wins China Approval for Ulcerative Colitis Drug VELSIPITY and Outlines Ambitious 2030 Growth Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2609855802","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609855802?lang=en_us&edition=fundamental","pubTime":"2026-02-06 12:08","pubTimestamp":1770350938,"startTime":"0","endTime":"0","summary":"The latest update is out from Everest Medicines Ltd. ( ($HK:1952) ). Everest Medicines has received approval from China’s National Medical Products...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/everest-medicines-wins-china-approval-for-ulcerative-colitis-drug-velsipity-and-outlines-ambitious-2030-growth-plan?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/everest-medicines-wins-china-approval-for-ulcerative-colitis-drug-velsipity-and-outlines-ambitious-2030-growth-plan?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MDCO"],"gpt_icon":0},{"id":"2609343490","title":"Everest Medicines Acquires License to Commercialize Kidney Drug MT1013","url":"https://stock-news.laohu8.com/highlight/detail?id=2609343490","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609343490?lang=en_us&edition=fundamental","pubTime":"2026-02-05 09:55","pubTimestamp":1770256547,"startTime":"0","endTime":"0","summary":"Everest Medicines (HKG:1952) acquired a license to MT1013 from Shaanxi Micot Pharmaceutical Technology to commercialize the drug, according to a Hong Kong bourse filing Thursday.The firm will pay 200 ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1583","01952","BK1161","MDCO","BK1574"],"gpt_icon":0},{"id":"2609794312","title":"Everest Medicines Announces Exclusive License Agreement with Micot to Commercialize MT1013","url":"https://stock-news.laohu8.com/highlight/detail?id=2609794312","media":"prnewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609794312?lang=en_us&edition=fundamental","pubTime":"2026-02-05 08:17","pubTimestamp":1770250620,"startTime":"0","endTime":"0","summary":"According to the agreement, Everest Medicines will pay Micot an upfront payment of RMB 200 million and potential regulatory and commercial milestone payments of up to RMB 1,040 million. MT1013 has entered Phase III clinical trial in China and the relevant development expenses will be covered by Micot. The strategic collaboration is expected to complement Everest Medicines' existing renal pipeline and drive operating synergies, further strengthen the Company's commercial product portfolio, and solidify its leading position in renal and autoimmune diseases in Asia, which are key therapeutic areas of focus. The collaboration will also expand the Company's nephrology portfolio from IgA nephropathy to a broader range of chronic kidney diseases .SHPT is one of the most common and serious complications in patients with CKD. It causes di","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/everest-medicines-announces-exclusive-license-agreement-with-micot-to-commercialize-mt1013-302679600.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCO","PTH","BK7095","PTH.AU","ASN.AU","BK7504"],"gpt_icon":0},{"id":"2609919314","title":"Everest Medicines Secures Exclusive Asian Rights to First-in-Class SHPT Drug MT1013","url":"https://stock-news.laohu8.com/highlight/detail?id=2609919314","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609919314?lang=en_us&edition=fundamental","pubTime":"2026-02-05 07:08","pubTimestamp":1770246524,"startTime":"0","endTime":"0","summary":"Everest Medicines Ltd. ( ($HK:1952) ) has provided an update. Everest Medicines’ China subsidiary has entered into an exclusive licensing agreement...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/everest-medicines-secures-exclusive-asian-rights-to-first-in-class-shpt-drug-mt1013?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/everest-medicines-secures-exclusive-asian-rights-to-first-in-class-shpt-drug-mt1013?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MDCO"],"gpt_icon":0},{"id":"2608360818","title":"BeOne Medicines Is Maintained at Overweight by Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2608360818","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608360818?lang=en_us&edition=fundamental","pubTime":"2026-02-04 22:08","pubTimestamp":1770214080,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ONC/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 04, 2026 09:08 ET (14:08 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCO"],"gpt_icon":0},{"id":"2608543823","title":"Analysts Offer Insights on Healthcare Companies: Amgen (AMGN) and BeOne Medicines (ONC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2608543823","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608543823?lang=en_us&edition=fundamental","pubTime":"2026-02-04 17:20","pubTimestamp":1770196854,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Amgen (AMGN – Research Report) and BeOne Medicines (...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-amgen-amgn-and-beone-medicines-onc-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-amgen-amgn-and-beone-medicines-onc-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","LU2468319806.SGD","XBI","IE00B2B36J28.USD","BK4599","LU2242646821.SGD","BK4139","LU0289739699.SGD","ONC","LU0889565916.HKD","BK4534","LU0128526141.USD","LU0029874061.USD","BK4533","LU1023059063.AUD","LU1983299246.USD","BK4585","LU0122379950.USD","IE00BFTCPJ56.SGD","LU0109394709.USD","IE00BJJMRZ35.SGD","LU1057294990.SGD","LU0320765992.SGD","HCSG","IE00B4R5TH58.HKD","LU2089984988.USD","SG9999001440.SGD","IE00BJT1NW94.SGD","MDCO","IE0009355771.USD","LU2112291526.USD","IE0002141913.USD","BK4581","BK4526","BK4566","XLV","LU2242652126.USD","LU0868494617.USD","LU1061106388.HKD","AMGN","LU0058720904.USD","BK4137","LU1571399168.USD","LABU"],"gpt_icon":0},{"id":"2608829489","title":"Everest Medicines Calls Virtual EGM to Approve Commercial Deal and New Share Incentive Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2608829489","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608829489?lang=en_us&edition=fundamental","pubTime":"2026-02-03 17:07","pubTimestamp":1770109674,"startTime":"0","endTime":"0","summary":"Everest Medicines Ltd. ( ($HK:1952) ) has issued an update. Everest Medicines Limited has called an extraordinary general meeting for 24 February 2...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/everest-medicines-calls-virtual-egm-to-approve-commercial-deal-and-new-share-incentive-plan?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/everest-medicines-calls-virtual-egm-to-approve-commercial-deal-and-new-share-incentive-plan?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MDCO"],"gpt_icon":0},{"id":"2608488416","title":"BeOne Medicines Extends InSysBio Tie Up To Refine Oncology Trial Dosing","url":"https://stock-news.laohu8.com/highlight/detail?id=2608488416","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608488416?lang=en_us&edition=fundamental","pubTime":"2026-02-02 01:26","pubTimestamp":1769966782,"startTime":"0","endTime":"0","summary":"BeOne Medicines (NasdaqGS:ONC) has extended its collaboration with InSysBio to apply mechanistic translational modeling to clinical trial design.\nThe partnership targets better dose selection and escalation strategies, with a specific focus on reducing the risk of cytokine release syndrome in upcoming studies.\nThis updated agreement aims to support the company’s clinical development plans for its novel therapies.\n\nFor you as an investor watching BeOne Medicines, the key point is that this is...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-onc/beone-medicines/news/beone-medicines-extends-insysbio-tie-up-to-refine-oncology-t","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-onc/beone-medicines/news/beone-medicines-extends-insysbio-tie-up-to-refine-oncology-t","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","MDCO","BK4526","ONC","BK4585"],"gpt_icon":0}],"pageSize":20,"totalPage":9,"pageCount":1,"totalSize":179,"code":"91000000","status":"200"}]}}